Últimas noticias sobre Keurig Dr Pepper (NASDAQ:KDP) Bolsa

Keurig Dr Pepper

Dr Pepper Snapple Group

Keurig Dr Pepper was established in 2018 following a merger between Keurig Green Mountain Coffee and Dr Pepper Snapple. The company manufactures and distributes coffee systems (including coffee brewers and single-serve coffee pods) under the Keurig and Green Mountain brands, as well as ready-to-drink beverages including flavored (non-cola) sparkling soft drinks under well-known brands such as Dr Pepper, Snapple, and Canada Dry. The company controls production and route to market for its own brands through in-house manufacturing plants and distribution infrastructure and leverages these facilities to manufacture and distribute for third-party coffee and beverage brands via licensing and partnership agreements. The US and Canada make up 95% of revenue, with the rest from Mexico.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

INTU

TCOM

WDAY

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: HD, KDP, TCOM, WDAY e INTU.

5 acciones en el foco este martes: HD, KDP, TCOM, WDAY e INTU

Keurig Dr Pepper Inc

Producer input prices fell far more than expected in March, aligning with a broader slowdown in consumer inflation seen the previous day, as the early effects of tariffs fail to materialize <a href="https://www.benzinga.com/news/econ-s">at the wholesale level.</a>
The Producer Price Index (PPI) increased by 2.7% year-over-year last month, well below the previous 3.2%, according to data released Friday by the Bureau of Labor Statistics. The figure was sharply below economists' forecast of 3.3%.
On a monthly basis, wholesale prices fell by 0.4% in March, following an upwardly revised 0.1% increase in February and missing expectations for a 0.2% gain. The decline was driven largely by goods prices, which accounted for over 70% of the drop in the index for final demand. 
Prices for final demand goods slipped 0.9%—the steepest monthly decline since October 2023, when they fell 1.4%. More than three-quarters of March's pullback in goods prices was due to a 4.0% drop in the index for final demand energy. Notably, gasoline prices plunged 11.1%, contributing to two-thirds of the overall decline in goods. 
Other categories that saw price drops included chicken eggs, beef and veal, fresh and dry vegetables, diesel fuel, and jet fuel. 
Core producer prices—excluding food and energy—rose 3.3% year-over-year, down from an upwardly revised 3.5% in February and below expectations of a rise to 3.6%. 
On a monthly basis, core inflation declined by 0.1%, reversing the 0.1% increase seen in February and falling short of the 0.3% gain economists had forecast.
<h3 class="wp-block-heading">Market Reactions</h3>
Futures on major U.S. indexes advanced by 8:37 a.m. ET, with S&amp;P 500 contracts up 0.6%, despite China raising U.S. tariffs to 125% overnight. 
Dow Jones futures led the gains, up 0.8%, lifted by stronger-than-expected earnings from major banks, including JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), and Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>). 
Meanwhile, the U.S. dollar index pared earlier losses slightly, while Treasury yields climbed, with the 10-year yield rising 7 basis points to 4.43%.
Gold futures were 1.5% higher to $3,225 per ounce. 
Premarket moves in major U.S. ETFs: 
<ul>
<li>SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) up 0.8%.</li>
<li>SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) up 0.9%. </li>
<li>Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) up 0.9%. </li>
<li>iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) up 0.7%. </li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44756353/xi-jinping-says-there-are-no-winners-in-tariff-war-as-china-slaps-125-tariffs-on-us-goods-urges-trump-to-immediately-correct-wrongdoings">Xi Jinping Says &#8216;There Are No Winners In Tariff War&#8217; As China Slaps 125% Tariffs On US Goods, Urges Trump To Immediately Correct &#8216;Wrongdoings&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

SPDR Dow Jones Industrial Average ETF Trust

Producer Inflation Cools Sharply In March, Yet Investors Show Muted Reaction

Truist Securities analyst David Macdonald maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Buy and raises the price target from $340 to $400.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Molina Healthcare, Raises Price Target to $400

Truist Securities analyst David Macdonald maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Hold and lowers the price target from $18 to $16.

Truist Securities Maintains Hold on Pediatrix Medical Group, Lowers Price Target to $16

NEOV

Neovolta, Virtual Peaker Collaborate To Enhance Grid Resilience And Accelerate Adoption Of Distributed Energy Resources

Truist Securities analyst David Macdonald maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and lowers the price target from $285 to $274.

Laboratory Corporation Of America Holdings

Truist Securities Maintains Buy on Labcorp Hldgs, Lowers Price Target to $274

Scotiabank analyst Cameron Bean upgrades CNX Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) from Sector Underperform to Sector Perform and announces $33 price target.

Upgrades

Scotiabank Upgrades CNX Resources to Sector Perform, Announces $33 Price Target

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
SPY is trading near our pivot at 530.09. Bulls need momentum above this level to initially target 531.57. If buyers remain dominant above this level, the next important zone would be 534.17, which could act as solid intraday support. Holding above that could set the stage for an advance towards 536.31. Our optimistic bull scenario today places SPY at a peak target of 538.30.
However, if SPY fails to sustain support at 530.09, bears could push prices down to test 527.36. A breach below this level under selling pressure would open up a test of 525.26. If bears seize control strongly here, expect continued downside momentum towards 522.84. Should the market experience aggressive selling, our low-end bear scenario targets a drop to 520.67.
Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
QQQ is hovering around our important zone of 450.98. Bulls must secure this level to move higher toward 452.98, establishing it as dependable intraday support. Persistent buying at these higher levels would signal strength toward 455.29, and potentially extend the rally to 457.55. Our maximum bullish target today for the QQQ stands at 460.55.
Conversely, failure to hold firmly above 450.98 would encourage bears to press aggressively downward to 447.73. If selling accelerates, expect further downside attempts toward 445.43. Sustained bearish momentum would likely see another significant test at 444.09, and if breached decisively, the day&#8217;s bearish objective is pegged at 441.56.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
Apple is currently testing the important support zone at 192.76. Bulls need strength at this level to move higher toward 193.95. If the bullish sentiment holds firm, the next upside target would be 194.83, with sustained buyer participation potentially driving the price action towards our peak bullish target for Apple today at 196.01.
Should Apple fail to maintain the 192.76 mark, expect bears to drive prices lower, testing the critical zone of 191.57. Persistent selling could see further decline towards 190.52, with additional weakness paving the way to test 189.44. A breach under sustained selling pressure would put our bearish scenario into play, targeting 188.20.
Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
Microsoft is actively trading near our pivotal support at 384.57. Bulls will look to hold firmly above this price, then aim higher toward 386.09 to solidify it as robust intraday support. A sustained rally above this level could initiate bullish continuation toward 388.53, with sustained buying potentially reaching our highest bullish target of the session at 390.98.
Alternatively, losing support at 384.57 would open up a test lower at 381.64. If selling pressure escalates, bears will likely push downward to 379.50. Continued bearish momentum would likely target 377.72, marking our day&#8217;s lowest bear objective for Microsoft.
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
NVIDIA is currently positioned around our important trading zone at 109.12. Bulls will aim for immediate upward movement to 110.73 and confirm this level as reliable intraday support. Additional bullish momentum could lift prices to 112.54, with continued strength likely propelling the auction towards 114.29. Our highest bull-side goal for NVIDIA today sits at 115.83.
If NVIDIA fails to maintain strength above 109.12, expect a bearish push down to 106.30. Continued bearish conviction would likely see a further test lower at 103.96, and if selling pressure intensifies, we anticipate a test at 101.02. Should this support falter, the bears&#8217; ultimate target today stands at 99.87.
Alphabet Inc Class A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)
Alphabet is auctioning around our critical price level of 154.95. Bulls must hold above this pivot, moving higher initially toward 156.61. Continued bullish dominance would increase the likelihood of seeing Alphabet test upward, targeting today&#8217;s high bullish price of 158.54.
If Alphabet loses support at 154.95, bears will likely initiate downside selling toward 153.93. Should selling intensify further, a bearish push to 152.94 could unfold. Under heavy selling conditions, we anticipate Alphabet potentially declining to our bearish target of 150.41.
Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
Meta is trading around our important pivot at 553.05. Bulls will need a solid push above this zone, targeting the next upside milestone at 565.53. Sustained bullish enthusiasm could lift the price action further towards 573.25, with continued upward momentum potentially reaching today&#8217;s maximum bullish target at 580.17.
Conversely, if Meta fails to maintain the 553.05 level, anticipate bears selling aggressively toward 541.79. Sustained selling pressure could further depress prices to 534.33. Under increasingly bearish conditions, Meta could decline to today&#8217;s lowest bearish scenario at 526.29.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla is auctioning near our critical pivot point of 252.38. Bulls are aiming to establish strength here, targeting a push higher towards 256.34. If buyers consistently step in at higher levels, the next key test would be at 259.81, potentially extending bullish momentum towards 262.68. Today&#8217;s optimistic bull scenario for Tesla sees the auction potentially reaching as high as 266.83.
However, if the price loses support at 252.38, bearish momentum could accelerate towards 248.37. Continued selling would likely press prices lower toward 246.16. Should this level fail decisively, expect further downside, with our ultimate bearish target on the day situated at 242.49.
Final Word:&nbsp;
Today's economic calendar features important data points beginning at 8:30 AM ET, with the release of the Producer Price Index (PPI) Final Demand for March. Following this, at 10 AM ET, markets will digest preliminary University of Michigan Consumer Sentiment figures, including Current Conditions, Consumer Expectations, and notably, the short and long-term inflation outlooks. Additionally, several influential Fed officials &#8211; Kashkari, Collins, Musalem, Williams, and Barkin &#8211; are scheduled to speak throughout the day, potentially impacting market sentiment with their remarks.
Given the backdrop of ongoing geopolitical tensions, escalating trade disputes, and tariff uncertainties, heightened volatility remains probable today, especially with weekly options contracts expiring. Traders should remain vigilant, practice disciplined risk management, and prepare for swift market movements. Best of luck navigating today&#8217;s volatility, and have a profitable Friday!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Technicals

Opinion

Signals

General

AAPL

GOOGL

MSFT

NVDA

TSLA

Trading Strategy For SPY, As Market Eyes PPI Data

Truist Securities analyst David Macdonald maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and raises the price target from $290 to $325.

Truist Securities Maintains Hold on Humana, Raises Price Target to $325

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Noah Poponak downgraded the rating for Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) from Buy to Neutral and lowered the price target from $6 to $3.5. Planet Labs shares closed at $3.36 on Thursday. <a href="https://www.benzinga.com/quote/pl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Noah Poponak downgraded the rating for Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowered the price target from $150 to $109. Booz Allen Hamilton shares closed at $108.81 on Thursday. <a href="https://www.benzinga.com/quote/bah/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Kristine Liwag downgraded Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) from Overweight to Equal-Weight and lowers the price target from $10 to $7. Joby Aviation shares closed at $6.02 on Thursday. <a href="https://www.benzinga.com/quote/joby/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andrew Andersen downgraded Skyward Specialty Insurance Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) from Buy to Hold and cut the price target from $62 to $59. Skyward Specialty shares closed at $52.15 on Thursday. <a href="https://www.benzinga.com/quote/skwd/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Mark Strouse downgraded the rating for Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Overweight to Neutral and lowered the price target from $14 to $7. Fluence Energy shares closed at $3.86 on Friday.  <a href="https://www.benzinga.com/quote/flnc/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BAH stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11081119/image-82-1024x584.png" alt="" class="wp-image-867807" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11081119/image-82-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11081119/image-82-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11081119/image-82-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11081119/image-82.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

Downgrades

CFLT

FLNC

JOBY

MTSI

SKWD

This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

In a pivotal year marked by the <a href="https://www.benzinga.com/news/25/01/43214683/target-ends-dei-program-following-trumps-call-to-eliminate-illegal-preferences-expert-calls-it-brand-suicide-for-retail-giant-with-diverse-customer-base">erosion of equity programs</a> and growing economic pressure, Higher 2025 will gather women of color from across the country in Philadelphia from June 27 to June 29. Now in its third year, the national conference is doubling down on its founding mission: to create sustainable, community-rooted systems that empower <a href="https://www.benzinga.com/markets/cannabis/23/03/31615646/women-of-color-cannabis-business-and-wellness-experience-set-for-june-in-philadelphia">women of color in cannabis</a>, wellness and entrepreneurship.
With this year's theme—"SOS: Saving Our Sisters, Saving Ourselves"—the event takes on renewed urgency. As political winds shift and support for diversity, equity, and inclusion initiatives weakens, the message behind Higher is clear: Survival and success will come not from institutions but from the communities themselves.
"Higher 2025 is about action. We are not just talking about solutions—we are creating them," said Sheena Roberson, founder of Higher. "This conference is a strategic investment in ourselves, our businesses, and our futures. It's about creating the systems we need to operate independently, together."
<h3 class="wp-block-heading">Action Over Rhetoric</h3>
Unlike other industry expos or networking summits, Higher is intentionally designed as a hands-on, resource-rich experience. It blends political engagement with business-building tools, healing spaces and cultural expression, creating a multi-layered space for women of color to strategize, connect and heal.
The programming at Higher 2025 is tailored to meet the real needs of attendees, many of whom operate at the intersection of systemic exclusion and emerging industries like cannabis.
Key program areas include:
<ul>
<li>The Higher Stage: A main platform for dialogue on policy, entrepreneurship and wellness, featuring leading voices from across sectors.</li>
<li>The Business Hub: A resource center providing legal support, contract education and direct pathways to funding and development.</li>
<li>The Real Estate Track: New this year, this track focuses on ownership, investment strategies and multigenerational wealth-building.</li>
<li>The Agriculture Track: Also debuting in 2025, this track emphasizes land access, sustainable farming and cannabis cultivation as tools for self-reliance.</li>
<li>The Tech Track: A forward-facing program exploring blockchain, AI and digital entrepreneurship for Women of Color entering high-growth sectors.</li>
<li>The Wellness Pavilion: A dedicated space for mental, emotional and physical healing, facilitated by doulas, therapists and other wellness practitioners.</li>
<li>Cultural &amp; Creative Activations: Live performances, art and storytelling celebrate identity and community resilience.</li>
<li>Nighttime Vibes: Social gatherings and curated networking events aimed at strengthening relationships beyond the boardroom.</li>
</ul>
Roberson, a longtime advocate for racial and gender equity in cannabis, sees this year&#8217;s event as a direct response to ongoing systemic rollbacks. For her, the path forward demands ownership—not just of businesses or land but of narratives, resources and community futures.
"This is not about waiting for change to come from outside forces," she said. "We are creating new economies, new networks, and new ways of being that reflect who we are and what we need."
<h3 class="wp-block-heading">A Movement Rooted In Reality</h3>
Higher 2025 arrives at a time when many women of color are being pushed out of formal equity programs, even as their communities bear the brunt of failed drug policies and underinvestment. The conference becomes more than an event in this environment—it is a declaration of intent and a site of collective problem-solving.
By emphasizing infrastructure and skill-sharing alongside healing and cultural celebration, Higher is shaping a model that others in the industry are beginning to look toward: one rooted not in performative support but in lived experience and practical tools for long-term survival.
Philadelphia, with its complex history and vibrant activist community, provides a fitting backdrop. The city has long served as a battleground for civil rights and economic justice. In 2025, it will again become a place where new paths are carved—this time by women of color determined to rewrite the story of who leads in cannabis and beyond.
Photo courtesy of Higher

Cannabis

Politics

Events

Higher 2025 Delivers Action-Focused Agenda For Women Of Color In Cannabis Industry

WIIM

Booz ALlen Hamilton shares are trading lower after Goldman Sachs downgraded the stock from Buy to Neutral and cut its price target from $150 to $109.

Truist Securities analyst David Macdonald maintains Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) with a Buy and raises the price target from $24 to $25.

GRDN

Truist Securities Maintains Buy on Guardian Pharmacy Service, Raises Price Target to $25

Truist Securities analyst David Macdonald maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Buy and raises the price target from $480 to $510.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Truist Securities Maintains Buy on Elevance Health, Raises Price Target to $510

Despite recent weakness, some traders believe Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">may be gearing up for a reversal</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1578</td>
<td>$23.5 billion</td>
<td>+1.1%</td>
<td>-2.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001195</td>
<td>$7.04 billion</td>
<td>+0.3%</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.056830</td>
<td>$2.9 billion</td>
<td>+1.5%</td>
<td>+0.05%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto outlet Bitcoinsensus <a href="https://x.com/Bitcoinsensus/status/1910422537269633086">highlighted</a> a potential Wyckoff Accumulation forming on DOGE's 4-hour chart — a classic pattern that often precedes large rallies.
If confirmed, it would signal that Dogecoin has bottomed and is building a solid base for a sustained uptrend.
Surf, another trader, sees a bullish signal if Dogecoin closes the month above the golden pocket. Meanwhile, Crypto Seth called DOGE one of the "cleanest charts" in the space right now, citing:
<ul>
<li>3D RSI is oversold with a bullish divergence</li>
<li>Strong momentum, structure and sentiment</li>
<li>Clear setup for a potential breakout</li>
</ul>
Seth <a href="https://x.com/seth_fin/status/1910633622421258654">concluded</a>, "Dogecoin is primed to take off."
Statistics: Coinglass data shows Dogecoin liquidations in the past 24 hours at $5.04 million, with long liquidations at $3.2 million. 
Bitinfocharts shows DOGE addresses holding 100 million to 1 billion DOGE spiked to 101 compared to 96 one month ago.
Community News: 21Shares, in collaboration with HouseOfDoge, <a href="https://x.com/21Shares/status/1909876206020837776">launched</a> the first Dogecoin ETP officially backed by the Dogecoin Foundation. 
The product is accessible via traditional banks or brokerages, with $1.24 billion in assets under management and 240,00 securities outstanding — a major milestone for DOGE&#8217;s institutional exposure.
What's Next: With chart patterns aligning, technical indicators flashing green, and whales accumulating, Dogecoin might be setting up for a powerful reversal. Traders are watching for confirmation; a breakout from the current accumulation range could be the signal that it's go-time for DOGE.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44698854/dogecoin-slides-17-in-7-days-what-is-going-on">Dogecoin Slides 17% In 7 Days: What Is Going On?</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin Up 1%: Is This A 'Healthy Bottom'?

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration's (FDA) <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs&amp;esheet=54236866&amp;newsitemid=20250411220656&amp;lan=en-US&amp;anchor=recent+decision&amp;index=1&amp;md5=8d7c209eadcf6aaf195cd961fb4e4efe">recent decision</a> to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products.
The FDA's announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise's mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary AI platform, LENSai&#x2122;.
"This policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology," said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. "IPA has long championed the transition toward more ethical, efficient, and accurate methodologies. Our AI-powered LENSai&#x2122; platform and suite of integrated discovery tools were designed precisely to support this new era of translational science."
IPA provides validated AI-driven methodologies that directly align with the FDA's shift towards New Approach Methodologies (NAMs). These advanced tools effectively address critical drug development challenges, including safety, toxicity, immunogenicity, and efficacy, by leveraging sophisticated predictive capabilities:
<ol>
<li>Safety and Toxicity Prediction: IPA's LENSai platform utilizes AI analytics to accurately predict potential toxicities by mapping drug interactions across the human proteome, significantly reducing the reliance on animal models.</li>
<li>Immunogenicity Screening: The platform identifies immunogenic hotspots and predicts potential adverse immune responses, reducing the risk of anti-drug antibody formation and optimizing patient-specific strategies.</li>
<li>Knowledge Graphs for Drug Efficacy: IPA's semantic knowledge graphs integrate biological data and scientific literature, enabling precise predictions of drug efficacy and interactions in human systems.</li>
</ol>
Through transitioning from animal testing to AI-driven methodologies, IPA aims to streamline preclinical workflows, reduce development costs, uphold higher ethical standards, and support regulatory compliance in line with the FDA's NAMs framework.

ImmunoPrecise Antibodies Announces Its Support For FDA's Recent Decision To Phase Out Animal Testing Requirements For Monoclonal Antibodies And Other Pharmaceutical Products

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities raised McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $665 to $755. B of A Securities analyst Michael Cherny maintained a Buy rating. McKesson shares closed at $679.33 on Thursday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital slashed the price target for Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) from $94 to $89. BMO Capital analyst James Thalacker maintained an Outperform rating. Entergy shares closed at $80.28 on Thursday. <a href="https://www.benzinga.com/quote/ETR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Susquehanna lowered Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) price target from $72 to $40. Susquehanna analyst Medhi Hosseini maintained a Neutral rating. Western Digital shares closed at $34.87 on Thursday. <a href="https://www.benzinga.com/quote/WDC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) from $26 to $18. Baird analyst Mark Altschwager maintained a Neutral rating. Capri shares closed at $14.63 on Thursday. <a href="https://www.benzinga.com/quote/CPRI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut the price target for Six Flags Entertainment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) from $64 to $52. Stifel analyst Steven Wieczynski maintained a Buy rating. Six Flags Entertainment shares closed at $32.29 on Thursday. <a href="https://www.benzinga.com/quote/FUN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley slashed Textron Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) price target from $82 to $71. Morgan Stanley analyst Kristine Liwag maintained an Equal-Weight rating. Textron shares settled at $64.52 on Thursday. <a href="https://www.benzinga.com/quote/TXT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler cut Steven Madden, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) price target from $35 to $25. Piper Sandler analyst Anna Andreeva maintained a Neutral rating. Steven Madden shares closed at $21.18 on Thursday. <a href="https://www.benzinga.com/quote/SHOO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham slashed CarMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) price target from $101 to $92. Needham analyst Chris Pierce maintained a Buy rating. CarMax shares closed at $60.45 on Thursday.  <a href="https://www.benzinga.com/quote/KMX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut the price target for American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) from $325 to $274. B of A Securities analyst Kenneth Bruce upgraded the stock from Neutral to Buy. American Express shares settled at $246.89 on Thursday. <a href="https://www.benzinga.com/quote/AXP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer slashed KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) price target from $850 to $700. Oppenheimer analyst Edward Yang maintained an Outperform rating. KLA shares closed at $656.76 on Thursday. <a href="https://www.benzinga.com/quote/KLAC/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MCK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="558" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11083928/image-83-1024x558.png" alt="" class="wp-image-867900" style="width:486px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11083928/image-83-1024x558.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11083928/image-83-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11083928/image-83-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11083928/image-83.png 1073w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

CPRI

KLAC

SHOO

McKesson To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday

Maxim Group analyst Thomas Forte initiates coverage on Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) with a Buy rating and announces Price Target of $14.

Initiation

BIRD

Maxim Group Initiates Coverage On Allbirds with Buy Rating, Announces Price Target of $14

Truist Securities analyst David Macdonald maintains Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) with a Hold and lowers the price target from $4 to $3.

Truist Securities Maintains Hold on Community Health Sys, Lowers Price Target to $3

Fortuna Mining Corp. (NYSE:<a href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>, TSX:<a href="https://www.benzinga.com/stock/FVI#TSX">FVI</a>) ("Fortuna" or the "Company") is pleased to announce it has entered into a definitive share purchase agreement (the "Agreement") to sell its interest in Roxgold Sanu SA ("Roxgold Sanu") which owns and operates the Yaramoko Mine, together with the Company's three other wholly-owned Burkina Faso subsidiaries which hold exploration permits in country (together with Roxgold Sanu, the "Acquired Companies") to Soleil Resources International Limited ("SRI") (the "Transaction"). SRI is a private Mauritius company which operates three mines, holds exploration permits, and owns a drilling company all in Burkina Faso. Following the completion of the Transaction, Fortuna will cease to have any operations in Burkina Faso.
Jorge A. Ganoza, President and CEO, commented, "Considering the limited remaining life of mineral reserves at Yaramoko (approximately one year), the cessation of our exploration activities in-country, and the increasingly challenging business climate in Burkina Faso, the Transaction represents a prudent exit that optimizes value, avoids approximately US$20 million in future mine closure liabilities, and provides Fortuna with additional liquidity as we pursue opportunities more closely aligned with our strategic objectives." Mr. Ganoza continued, "We believe that Soleil, as a private local company, is well positioned to continue operations at the Yaramoko Mine to the benefit of employees and local stakeholders".
Details of the Transaction
Under the terms of the Agreement, SRI will acquire all of the issued and outstanding shares of the Acquired Companies. Fortuna will receive an aggregate cash payment of approximately US$130 million as follows:
<ul>
<li>US$70 million consideration payable on closing of the Transaction;</li>
<li>US$57.5 million in cash dividends (the "Cash Dividend") paid to Fortuna by Roxgold Sanu; and</li>
<li>Fortuna will also have the right to receive up to approximately US$53 million of value added tax receivables upon the completion of certain conditions. &nbsp;</li>
</ul>
The completion of the Transaction is subject to the payment by Roxgold Sanu to Fortuna of the Cash Dividend, receipt of the consent of the Minister of Mines, and customary conditions of closing for transactions of this nature and is expected to be completed in the second quarter of 2025.

Fortuna Mining Enters Into a Definitive Share Purchase Agreement To Sell Its Interest in Roxgold Sanu SA Which Owns and Operates the Yaramoko Mine For An Aggregate Cash Payment Of ~$130M

Truist Securities analyst David Macdonald maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $76 to $82.

Truist Securities Maintains Buy on CVS Health, Raises Price Target to $82

Dividends

Press Releases

Keurig Dr Pepper Declares Quarterly Dividend

Keurig Dr Pepper Evolves Executive Leadership Team in Support of Growth Strategy

Keurig Dr Pepper to Report Fourth Quarter 2024 Results and Host Conference Call

Keurig Dr Pepper Unveils Bold New Flavors Across Iconic U.S. Cold Beverages Portfolio

Keurig Dr Pepper Reports Q4 and Full Year 2024 Results and Provides 2025 Outlook

Offerings

Keurig Dr Pepper Announces Secondary Offering of Common Stock by JAB

Keurig Dr Pepper Announces Pricing of Secondary Offering of Common Stock by JAB

Keurig Dr Pepper to Report First Quarter 2025 Results and Host Conference Call

Entertainment

SNAPPLE® NAMED OFFICIAL TEA PARTNER OF THE NEW YORK KNICKS, NEW YORK RANGERS AND MADISON SQUARE GARDEN

MSGE

MSGS

Embotelladora Andina S.A. Common Stock

Celsius Holdings

The Vita Coco Company, Inc. - Common Stock

Vita Coco

Coca-Cola Consolidated, Inc. - Common Stock

Coca-Cola Consolidated

National Beverage

Fomento Economico Mexicano S.A.B. de C.V. Common Stock

Fomento Economico

Coca-Cola

Coca Cola Femsa S.A.B. de C.V. American Depositary Shares, each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L Shares)

Comments

Keurig Dr Pepper

Noticias

Últimas noticias sobre Keurig Dr Pepper (NASDAQ:KDP) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL